ArticleFrontiers in oncology2026
Development and validation of a multifactorial risk prediction model for breast cancer patients with co-occurring thyroid cancer: a retrospective matched case-control study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate a multifactorial machine learning model predicting thyroid cancer (TC) co-occurrence risk in breast cancer (BC) patients. Methods: This single-center retrospective matched case-control study analyzed 400 BC patients (200 with co-occurring TC, 200 matched BC-only controls) diagnosed between 2012-2025. Predictors included demographic, clinical, hormonal, and tumor biological variables. After feature selection via LASSO regression to handle multicollinearity, four machine learning algorithms (logistic regression, random forest, XGBoost, SVM) were developed and optimized using Bayesian hyperparameter tuning with 5-fold cross-validation. Model performance was evaluated on a 30% independent test set using AUC-ROC, calibration curves, and decision curve analysis. Results: Multivariate analysis identified independent risk factors for TC co-occurrence: radiotherapy history (aOR = 3.42, 95% CI: 2.14-5.46), elevated TSH level (aOR = 2.01 per µIU/mL, 95% CI: 1.65-2.45), ER-positive status (aOR = 2.47, 95% CI: 1.43-4.28), family history of TC (aOR = 3.05, 95% CI: 1.55-6.00), and younger age at BC diagnosis (aOR = 1.07 per year decrease, 95% CI: 1.04-1.10). The XGBoost model demonstrated superior discrimination (test AUC = 0.874, 95% CI: 0.836-0.934) compared to other algorithms, with 86.7% accuracy, 83.3% sensitivity, and 90.0% specificity. Notably, subgroup analysis revealed enhanced predictive performance in patients with a history of radiotherapy (AUC = 0.921). Decision curve analysis confirmed clinical utility across threshold probabilities (20-80%), showing a superior net benefit for personalized risk stratification. Conclusion: The XGBoost-based model integrates radiotherapy exposure, hormonal profiles, and tumor biology to stratify TC risk in BC patients. It offers a clinically applicable tool for personalized surveillance, balancing early detection with resource optimization. External validation is warranted before implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.